Collegium Pharmaceutical (NASDAQ:COLL) – Research analysts at William Blair upped their Q1 2018 earnings per share estimates for Collegium Pharmaceutical in a report released on Monday, April 16th. William Blair analyst T. Lugo now anticipates that the specialty pharmaceutical company will earn ($0.73) per share for the quarter, up from their previous forecast of ($0.79). William Blair has a “Outperform” rating on the stock. William Blair also issued estimates for Collegium Pharmaceutical’s Q2 2018 earnings at ($0.23) EPS, Q3 2018 earnings at ($0.05) EPS, Q4 2018 earnings at $0.15 EPS and FY2018 earnings at ($0.84) EPS.
Other equities analysts have also issued reports about the company. BidaskClub upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Thursday, February 15th. Jefferies Group upped their target price on Collegium Pharmaceutical to $32.00 and gave the company a “buy” rating in a research note on Monday, February 12th. Piper Jaffray set a $33.00 price target on Collegium Pharmaceutical and gave the company a “buy” rating in a research report on Monday, February 12th. Needham & Company LLC boosted their price target on Collegium Pharmaceutical from $28.00 to $35.00 and gave the company a “buy” rating in a research report on Wednesday, February 7th. Finally, Janney Montgomery Scott set a $26.00 price target on Collegium Pharmaceutical and gave the company a “buy” rating in a research report on Tuesday, February 6th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $30.83.
Collegium Pharmaceutical stock opened at $24.89 on Wednesday. The firm has a market capitalization of $766.24, a P/E ratio of -10.08 and a beta of 0.76. Collegium Pharmaceutical has a 52 week low of $7.37 and a 52 week high of $29.90.
Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Wednesday, March 7th. The specialty pharmaceutical company reported ($0.54) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.56) by $0.02. The firm had revenue of $10.79 million during the quarter, compared to analyst estimates of $9.88 million. Collegium Pharmaceutical had a negative return on equity of 73.00% and a negative net margin of 262.91%. The firm’s revenue was up 728.4% compared to the same quarter last year.
In other Collegium Pharmaceutical news, Chairman Michael Thomas Heffernan sold 20,000 shares of the business’s stock in a transaction dated Tuesday, January 23rd. The stock was sold at an average price of $25.01, for a total transaction of $500,200.00. Following the completion of the sale, the chairman now owns 535,395 shares of the company’s stock, valued at $13,390,228.95. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 25.76% of the stock is currently owned by insiders.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Macquarie Group Ltd. boosted its position in shares of Collegium Pharmaceutical by 21.5% in the fourth quarter. Macquarie Group Ltd. now owns 1,616,117 shares of the specialty pharmaceutical company’s stock worth $29,833,000 after buying an additional 286,138 shares during the period. LPL Financial LLC boosted its position in shares of Collegium Pharmaceutical by 6.4% in the fourth quarter. LPL Financial LLC now owns 151,085 shares of the specialty pharmaceutical company’s stock worth $2,789,000 after buying an additional 9,082 shares during the period. Teachers Advisors LLC boosted its position in shares of Collegium Pharmaceutical by 11.3% in the fourth quarter. Teachers Advisors LLC now owns 66,533 shares of the specialty pharmaceutical company’s stock worth $1,228,000 after buying an additional 6,739 shares during the period. Raymond James & Associates purchased a new stake in shares of Collegium Pharmaceutical in the fourth quarter worth about $389,000. Finally, California State Teachers Retirement System boosted its position in shares of Collegium Pharmaceutical by 10.5% in the fourth quarter. California State Teachers Retirement System now owns 39,499 shares of the specialty pharmaceutical company’s stock worth $729,000 after buying an additional 3,752 shares during the period. 86.39% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: “Q1 2018 EPS Estimates for Collegium Pharmaceutical (COLL) Increased by Analyst” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/04/19/q1-2018-eps-estimates-for-collegium-pharmaceutical-coll-increased-by-analyst.html.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.